Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients

Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients Letters to the Editor e285 Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients To the Editor: In the quantitative analysis, publication bias and heterogeneity between the studies included was as- sessed. Finally pooled measure as the odds ratio INTRODUCTION (OR) and 95% confidence interval (95% CI) was calcu- lated. A random effects model was used due to the COVID-19 disease usually presents with mild symp- heterogeneity between the included studies. tomatology. However, some people may develop 1,2 more severe symptoms as pneumonia with severe acute respiratory distress syndrome (ARDS), mediated RESULTS by a number of proinflammatory cytokines, such as IL- 2,5 6TNF-a IL-17, GM-CSF, and G-CSF. Therefore, Seven full-text articles (5 retrospective, 1 prospective, cytokine-blocking drugs have been supposed to be and 1 randomized clinical trial) were included in the 9–15 effective in the treatment of disease. Research sug- revision. Risk of bias assessment suggest that main 10–16 gests that drugs as selective serotonin reuptake inhib- bias observed was confounding bias and bias in 11,14,15 itors (SSRIs) used as antidepressants may be useful in the measurement of results. Selection bias also the treatment of SARS-CoV2 because they inhibit appears in 2 of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Therapeutics Wolters Kluwer Health

Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients

Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/antidepressants-are-associated-with-a-reduction-in-the-risk-of-death-l42BT3q0WG

References (26)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1075-2765
eISSN
1536-3686
DOI
10.1097/mjt.0000000000001618
Publisher site
See Article on Publisher Site

Abstract

Letters to the Editor e285 Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients To the Editor: In the quantitative analysis, publication bias and heterogeneity between the studies included was as- sessed. Finally pooled measure as the odds ratio INTRODUCTION (OR) and 95% confidence interval (95% CI) was calcu- lated. A random effects model was used due to the COVID-19 disease usually presents with mild symp- heterogeneity between the included studies. tomatology. However, some people may develop 1,2 more severe symptoms as pneumonia with severe acute respiratory distress syndrome (ARDS), mediated RESULTS by a number of proinflammatory cytokines, such as IL- 2,5 6TNF-a IL-17, GM-CSF, and G-CSF. Therefore, Seven full-text articles (5 retrospective, 1 prospective, cytokine-blocking drugs have been supposed to be and 1 randomized clinical trial) were included in the 9–15 effective in the treatment of disease. Research sug- revision. Risk of bias assessment suggest that main 10–16 gests that drugs as selective serotonin reuptake inhib- bias observed was confounding bias and bias in 11,14,15 itors (SSRIs) used as antidepressants may be useful in the measurement of results. Selection bias also the treatment of SARS-CoV2 because they inhibit appears in 2 of

Journal

American Journal of Therapeutics – Wolters Kluwer Health

Published: Feb 28, 2023

There are no references for this article.